RA
FENC icon

Rosalind Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Rosalind Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3M Buy
3,188,001
+279,800
+10% +$2.28M 12.73% 2
2026
Q1 		$17.9M Buy
2,908,201
+294,693
+11% +$2.28M 7.19% 3
2025
Q4 		$20.1M Buy
2,613,508
+536,668
+26% +$4.41M 7.07% 3
2025
Q3 		$19.4M Buy
2,076,840
+31,196
+2% +$270K 6.64% 3
2025
Q2 		$17M Buy
2,045,644
+262,800
+15% +$1.8M 8.05% 2
2025
Q1 		$10.9M Buy
1,782,844
+522,968
+42% +$3.36M 5.28% 6
2024
Q4 		$7.96M Buy
+1,259,876
New +$6.45M 4.07% 10

Other funds holding FENC

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM

Rosalind Advisors's FENC Position: Q2 2026 in Review

Rosalind Advisors increased its Fennec Pharmaceuticals (FENC) stake by 9.6% in Q2 2026, buying an estimated $2.28M and bringing the position to 3,188,001 shares worth $34.3M. The position accounts for 12.73% of the portfolio, ranked #2.

Rosalind Advisors first reported a position in FENC in Q4 2024 and has held it in 7 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Rosalind Advisors held 3,188,001 shares of Fennec Pharmaceuticals worth $34.3M as of Q2 2026.
  • Rosalind Advisors bought 279,800 Fennec Pharmaceuticals shares in Q2 2026, an estimated $2.28M.
  • Fennec Pharmaceuticals made up 12.73% of Rosalind Advisors's portfolio in Q2 2026, its #2 holding.
  • Rosalind Advisors first reported a position in Fennec Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.